Trial Profile
Radiation and Chemotherapy With Ipilimumab Followed by Nivolumab for Patients With Stage III Unresectable NSCLC
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 13 Jul 2023
Price :
$35
*
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- 26 Jun 2023 Results assessing the safety (phase 1) and the 12-month progression-free survival (PFS) (phase 2) in a multi-institution prospective trial published in the International Journal of Radiation Oncology, Biology, Physics
- 14 Feb 2023 Status changed from active, no longer recruiting to discontinued.
- 29 Jul 2021 Status changed from recruiting to active, no longer recruiting.